Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.
Their new study, published online on July 1, 2021 in Cell Reports Medicine, shows that both CD4+ “helper” T cells and CD8+ “killer” T cells can still recognize mutated forms of the virus. This reactivity is key to the body’s complex immune response to the virus, which allows the body to kill infected cells and stop severe infections.
- Read more about Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/moderna-and-pfizer-biontech-vaccines-prime-t-cells-to-fight-sars-cov-2-variants
No comments:
Post a Comment